Coverage
-
February 05, 2016
Supernus Pharmaceuticals Inc. won a partial victory Friday in its bid to stop Actavis Inc. from bringing a generic version of the epilepsy drug Oxtellar XR to market when a New Jersey federal judge ruled the planned generic would infringe two Supernus patents.
2 other articles on this case.
View all »